EyePoint Pharmaceuticals

Press Releases

pSivida New Board Appointments
Jul 14, 2008
pSivida New Board Appointments Boston, MA (July 14, 2008) – pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PSI), a leading drug delivery company headquartered in Watertown, MA, is pleased to announce the appointment to their Board of Directors of Peter G. Savas and Paul A.
pSivida Corp: BrachySil™ Phase IIb Pancreatic Cancer Trials Commence
Jul 07, 2008
pSivida Corp: BrachySil™ Phase IIb Pancreatic Cancer Trials Commence Boston, MA. and Perth, Australia (July 7, 2008) – pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FF: PSI), a global drug delivery company is pleased to announce that a Phase IIb clinical trial has commenced with BrachySil™ (P32
pSivida MD to ring NASDAQ Closing Bell
Jul 01, 2008
pSivida MD to ring NASDAQ Closing Bell Boston, MA and Perth, Australia (June 30, 2008) – Global drug delivery company, pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FSE: PSI) today announced that Dr. Paul Ashton, Managing Director, will ring the NASDAQ Stock Market Closing Bell on Tuesday, July 1, at 4
pSivida Interim results from the 3-month Human PK Medidur FA Study
Jun 27, 2008
pSivida Interim results from the 3-month Human PK Medidur FA Study Boston, MA and Perth, Australia (June 27, 2008) – Global drug delivery company, pSivida Corp. (NASDAQ: PSDV, ASX: PVA, FSE: PSI) today reported the interim three-month safety and efficacy results from the first human
Open Briefing Interview with Managing Director, Dr Paul Ashton - pSivida reincorporation in the US
Jun 20, 2008
Open Briefing Interview with Managing Director, Dr Paul Ashton - pSivida reincorporation in the US Date of lodgement: 20-Jun-2008 Title: Open Briefing®. pSivida. Reincorporation of pSivida to US Record of interview: corporatefile.com.au pSivida Ltd. (NASDAQ:PSDVV, ASX:PVA, FSE:PSI) has implemented
pSivida Scheme of Arrangement Implemented
Jun 19, 2008
pSivida Scheme of Arrangement Implemented Boston, MA and Perth, Australia (19 June 2008) - pSivida Corp. (ASX: PVA, NASDAQ: PSDVV, FSE: PSI) announces that the Scheme of Arrangement between pSivida Limited and its shareholders has today been implemented.
Jun 12, 2008
Jun 11, 2008
Compliance with ASX Listing Rule 3.1
Jun 11, 2008
Compliance with ASX Listing Rule 3.1 Boston, MA and Perth, Australia (11 June 2008) - pSivida Limited. (ASX: PSD, NASDAQ: PSDV, FSE: PSI) confirms that it is in compliance with its obligations under ASX Listing Rule 3.1 as at the date of this announcement.
Jun 11, 2008
NASDAQ Trading To Commence
Jun 11, 2008
NASDAQ Trading To Commence Boston, MA and Perth, Australia (June 11, 2008) – Following approval by the Federal Court of Australia of the reincorporation of pSivida Limited, a Western Australian corporation, to pSivida Corp., a new Delaware, United States corporation, pSivida Corp.
Jun 11, 2008
Jun 10, 2008
Jun 06, 2008
Jun 06, 2008
Jun 06, 2008
Jun 04, 2008
pSivida to present at the Rodman & Renshaw Healthcare Conference in Monte Carlo
May 19, 2008
pSivida to present at the Rodman & Renshaw Healthcare Conference in Monte Carlo Boston, MA and Perth, Australia – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced that the Company’s Managing Director, Dr Paul Ashton is making a company presentation today at the Rodman & Renshaw 5th
pSivida new trial to treat AMD (age related macular degeneration)
May 09, 2008
pSivida new trial to treat AMD (age related macular degeneration) Boston, MA. and Perth, Australia – pSivida Limited (ASX: PSD, NASDAQ: PSDV, FSE: PSI) announced today that enrolment has begun for a clinical trial to assess the safety and efficacy of Medidur™ FA in conjunction with Lucentis®
Shareholder Meeting - 6 June 2008
May 06, 2008
Shareholder Meeting - 6 June 2008 Boston, MA. and Perth, Australia – pSivida Limited (ASX: PSD, NASDAQ: PSDV, FSE: PSI) announced today that the Federal Court of Australia had ordered the convening of a meeting of shareholders to be held on 6 June 2008 to vote on the proposed Scheme of Arrangement
Displaying 321 - 340 of 352
EyePoint Pharmaceuticals